E-TACE with donafenib for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combined treatment for liver cancer that cannot be removed with surgery. It combines a targeted therapy pill (donafenib) with a procedure that delivers chemotherapy directly to the tumor (E-TACE). The goal is to see if this combination helps control the cancer and is safe for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have liver cancer that cannot be removed with surgery, but it is not diffuse (spread throughout the liver).
- You have not had certain previous treatments for your liver cancer, such as TACE, radiation, or targeted therapy.
- You are able to take care of yourself (ECOG score 0-1) and your expected survival is at least 3 months.
- Your liver and kidney function are adequate (Child-Pugh A or B) and blood tests meet required levels.
- You do not have major bleeding risk, serious heart conditions, or other untreated cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy, immunotherapy, and a liver-directed therapy given before surgery to shrink tumors in people with early-stage liver cancer that can be removed. The goal is to make surgery more successful and improve outcomes.
This trial tests a drug called Donafenib (a targeted therapy) taken after surgery to see if it can prevent liver cancer from coming back in people at high risk of recurrence.
This trial tests whether taking the drug donafenib after a procedure called ablation (which destroys liver tumors) can help keep your liver cancer from returning. It is for people whose liver cancer has come back within the past year and who have small, treatable tumors.
This trial tests a new combination of three drugs for people with advanced liver cancer whose disease got worse after their first treatment. The goal is to see if this new mix can help control the cancer better and give patients more time.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.